I don't think we'll see too many surprises on the downside, as we're really in bargain basement territory here.

The chronic pain market will likely undergo a major sea change over the next few years and there are significant investment opportunities yet to be recognized.

We want to get people excited about VCP. And we want to encourage researchers to focus on things important to our clients.

We want to get people excited [about VCP]. And we want to encourage researchers to focus on things important to our clients.

This slowdown is expected because they are exhausting their cost-savings from the merger. But their earnings growth in 2003 and beyond will still be above most of their peers', thanks to strong drug sales.

With AHP we'll be looking at everything, just like Pfizer.